Search jobs 17-May-2021 IcanoMAB Announces a Novel IL-18 Signaling Blocker (anti-IL-1R7) Ready for Development for the Treatment of the Cytokine-Release-Syndrome in Late-stage Covid-19
Positive regulatory advice received for development plan to provide POC in late-stage COVID-19 patients
Additional opportunities in indications related to Cytokine-Release Syndrome, e.g., ARDS, MAS and acute inflammatory diseases
Pre-clinical proof-of-concept recently published with Charles Dinarello, University of Colorado, Denver
Partner discussions in preparation to exploit full therapeutic potential
POLLING, Germany, May 17, 2021 / B3C newswire / IcanoMAB, a privately-funded biotech company focusing on the pre-clinical and clinical development of novel precision antibodies for the treatment of cancer, immune-system related diseases and COVID-19, today announced that it has received positive regulatory advice for the clinical development path
Explained: When And Why Does A Covid-19 Patient Need Oxygen Support?
Covid explained: A Covid-19 patient needs oxygen support when shortness of breath progresses to a more acute condition.
Outlook Web Bureau 17 May 2021, Last Updated at 7:38 am File photo Outlook Web Bureau 2021-05-17T07:36:44+05:30 Explained: When And Why Does A Covid-19 Patient Need Oxygen Support? outlookindia.com 2021-05-17T07:38:57+05:30
Also read
The ongoing second surge in Covid-19 cases has seen a huge rise in the demand for supplemental oxygen. According to the data with the National Clinical Registry, a new emerging trend during the second wave has been witnessed – Shortness of breath is the most common clinical feature among symptomatic hospitalised patients at 47.5 per cent, compared to 41.7 per cent during the first wave.
Share this article
Share this article
CRANFORD, N.J., May 17, 2021 /PRNewswire/ Citius Pharmaceuticals, Inc. ( Citius or the Company ) (Nasdaq: CTXR) today announced that Ilanit Allen has been appointed Vice President of Corporate Communications and Investor Relations, effective immediately. In this newly created role, Ms. Allen will spearhead financial communication and investor activities, reporting to Myron Holubiak, President and Chief Executive Officer of Citius. We are thrilled to welcome Ilanit to the Citius team as we advance our pipeline of first-in-class critical care products, stated Mr. Holubiak. I am confident that Ilanit s extensive communications and investor relations experience, coupled with her financial and strategic mindset, will be an invaluable resource for our investors and the broader financial community. With multiple expected milestones on the horizon, we look forward to leveraging Ilanit s expertise in communicating the Citius story with our sta
Edesa Biotech Reports Fiscal 2nd Quarter 2021 Results
ACCESSWIRE
14 May 2021, 22:05 GMT+10
TORONTO, ON / ACCESSWIRE / May 14, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three and six months ended March 31, 2021 and provided an update on its business.
The company reported that it has enrolled more than 285 patients in an ongoing Phase 2/3 clinical study of its investigational drug, EB05, as a single-dose treatment for hospitalized COVID-19 patients with or at risk of developing Acute Respiratory Distress Syndrome (ARDS). ARDS is the leading cause of death in COVID-19 patients. The study is being funded in part by a C$14 million reimbursement grant from the Canadian Government. In addition, Edesa completed enrollment of the first cohort of a Phase 2b clinical study evaluating another drug candidate, EB01, as a monotherapy for chronic Allergic Conta
Knoxville Biz Ticker: United Community Banks, Inc. announces acquisition of FinTrust Capital Partners, LLC
The Knoxville News-Sentinel 2 hrs ago Knoxville News Sentinel
United Community Banks, Inc. announces acquisition of FinTrust Capital Partners, LLC
GREENVILLE, S.C. – May 13, 2021 – United Community Banks, Inc. (NASDAQ: UCBI) (United) today announced that its Advisory Services division will be expanding through the acquisition of FinTrust Capital Partners, LLC (FinTrust), and its operating subsidiaries FinTrust Capital Advisors, LLC, FinTrust Capital Benefit Group, LLC and FinTrust Brokerage Services, LLC. FinTrust is a 13-year-old employee-owned investment advisory firm headquartered in Greenville, South Carolina, with additional locations in Anderson, South Carolina, and Athens and Macon, Georgia. The firm provides wealth and investment management services to individuals and institutions within its markets. As of March 31, 2021, FinTrust had assets u